Data from a prospective phase II study investigating the neoadjuvant immunotherapy with Dostarlimab (an anti-PD-1 monoclonal antibody) of locally advanced (stage II or III) rectal adenocarcinoma reported that among 16 enrolled patients, 12 completed treatment, and all these (100%) presented clinical complete response defined as no evidence of residual tumor at imaging, endoscopy, or biopsy [132]. The gene discussed is PDCD1; the disease is neoplasm.